PREX2 and non-small cell lung carcinoma: Patients with TP53 (median survival time, 27 months vs. 62 months; P = 0.0056), PREX2 (median survival time, 8 months vs. 42 months; P < 0.001), ARID1A (median survival time, 10 months vs. 44 months; P < 0.0001), PTPRT (median survival time, 8 months vs. 44 months; P < 0.0001) and PIK3CG (median survival time, 24 months vs. 42 months; P = 0.036) mutations survived for a significantly shorter period than those without the mutations, suggesting that these mutations predict positive factors for NSCLC prognosis (Fig. 4A-E).